Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 8/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.36 |
| ▸ | RORC | P51449 | 8/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | GCKR | Q14397 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102209 | 1.00 | NR1H2 (0.36) | NR1H2NR1H3RORCNR1I2MCHR1 | |
| SCHEMBL102211 | 1.00 | NR1H2 (0.36) | NR1H2NR1H3RORCNR1I2MCHR1 | |
| SCHEMBL102208 | 1.00 | NR1H2 (0.36) | NR1H2NR1H3RORCNR1I2MCHR1 | |
| SCHEMBL16549825 | 0.83 | SIGMAR1 (0.31) | MCHR1 | |
| SCHEMBL3595439 | 0.83 | RAD52 (0.36) | NR1H2NR1H3RORCNR1I2HTR2C | |
| SCHEMBL3595444 | 0.83 | RAD52 (0.36) | NR1H2NR1H3RORCNR1I2HTR2C | |
| SCHEMBL3595436 | 0.83 | RAD52 (0.36) | NR1H2NR1H3RORCNR1I2HTR2C | |
| SCHEMBL3595442 | 0.83 | RAD52 (0.36) | NR1H2NR1H3RORCNR1I2HTR2C | |
| SCHEMBL105424 | 0.81 | — | — | |
| SCHEMBL105423 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | NR1H2 1/4885NR1H3 2/4885RORC 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.